Exploring potential predictive biomarkers through historical perspectives on the evolution of systemic therapies into the emergence of neoadjuvant therapy for the treatment of hepatocellular carcinoma

Hepatocellular carcinoma (HCC), a type of liver cancer, ranks as the sixth most prevalent cancer globally and represents the third leading cause of cancer-related deaths. Approximately half of HCC patients miss the opportunity for curative treatment and are then limited to undergoing systemic therap...

Celý popis

Podrobná bibliografie

Hlavní autoři:	Chuanlei Wang, Feng Wei, Xiaodong Sun, Wei Qiu, Ying Yu, Dawei Sun, Yao Zhi, Jing Li, Zhongqi Fan, Guoyue Lv, Guangyi Wang
Médium:	Artigo
Jazyk:	Inglês
Vydáno:	Frontiers Media S.A. 2024-06-01
Edice:	Frontiers in Oncology
Témata:	hepatocellular carcinoma IMbrave150 trial immunotherapy immune-checkpoint inhibitors neoadjuvant therapy
On-line přístup:	https://www.frontiersin.org/articles/10.3389/fonc.2024.1429919/full
Tagy:	Přidat tag Žádné tagy, Buďte první, kdo vytvoří štítek k tomuto záznamu!